Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine

BMC Neurology

Table 3 Treatment effects in the socioeconomic model

Variable	Average value pre-treatment	Average value post-treatment	Difference	Difference (%)	p-value	n
Sick days (hours lost)^a	5.00	3.59	1.41	28.2%	0.120	29
Presenteeism^b	0.73	0.59	0.14	18.8%	0.004	29
Working part-time (hours worked)^c	22.00	25.88	+ 3.88	17.6%	0.314	17
Labour market participation^d	49.83%		-	-	0.026	6
Educational attainment^d	35.31%		-	-	0.002	13
Career choice^d	39.05%		-	-	0.000	19

Statistical significance was estimated using Wilcoxon signed-rank test on the null hypothesis of no difference in population mean ranks.
^a Sick days are measured b they Working Productivity and Activity Impairment (WPAI) Item 2 [31]. In Item 2, respondents are asked about hours lost at work in the previous seven days due to migraine.
^b Presenteeism is measured by the Standard Presenteeism Scale (SPS-6) [26]. In this study, the scoring is inverted and normalised to a scale between 0 and 1.
^c Measured by the weekly hours worked.
^d For labour market participation, educational attainment, and career choice, before and after values and hence differences cannot be calculated.

ISSN: 1471-2377